文献速递头颈与中枢神经肿瘤支持与姑息治疗

富勒烯降低头颈癌放疗急性放射性皮炎:II期双盲随机对照试验

Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2026-03-20

这项II期双盲随机对照试验纳入132例接受放疗的头颈癌患者,1:1分配至富勒烯或三乙醇胺组,从放疗前3天至放疗后14天每日三次涂抹。主要终点为≥2级急性放射性皮炎发生率,富勒烯组为34.8%(95%CI 24.5-46.9),显著低于三乙醇胺组的83.3%(95%CI 72.6-90.4)。

要点

  • 富勒烯组≥2级急性放射性皮炎发生率为34.8%,三乙醇胺组为83.3%。
  • 试验为II期双盲随机对照,共132例头颈癌放疗患者,1:1分组。
  • 用法为放疗前3天至放疗后14天,每日涂抹三次。

核心结论

  • 与三乙醇胺相比,富勒烯显著降低头颈癌放疗患者≥2级急性放射性皮炎的发生率。

研究设计与样本

  • II期双盲随机对照试验,于四川大学华西医院2024年8月至2025年3月开展。
  • 共132例接受放疗的头颈癌患者按1:1随机分配至富勒烯组(66例)或三乙醇胺组(66例)。
  • 患者平均年龄58.0岁(标准差11.1),女性39例(29.5%)。
  • 主要终点为意向治疗人群中≥2级急性放射性皮炎的发生率。

主要发现

  • 富勒烯组≥2级急性放射性皮炎发生率为34.8%(95%CI 24.5-46.9)。
  • 三乙醇胺组≥2级急性放射性皮炎发生率为83.3%(95%CI 72.6-90.4)。

临床怎么用

  • 头颈癌放疗患者可从放疗前3天至放疗后14天每日三次涂抹富勒烯,以降低≥2级急性放射性皮炎风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Acute radiation dermatitis (ARD) is a common debilitating toxicity in patients with head and neck cancer receiving radiotherapy. Current evidence-based strategies for preventing ARD remain limited, and alternative approaches are needed to optimize care. METHODS: In this double-blind, randomized, controlled phase II trial, eligible patients with head and neck cancer undergoing radiotherapy were randomly assigned in a 1:1 ratio to receive either fullerene or trolamine at West China Hospital, Sichuan University, from August 2024 to March 2025. Participants were instructed to apply the assigned cream three times daily starting from the 3 days before radiotherapy and continuing for 14 days after completion of radiotherapy. ARD was evaluated weekly during radiotherapy and for 4 weeks after radiotherapy. The primary end point was the incidence of grade ≥2 ARD, assessed in the intention-to-treat population. RESULTS: A total of 132 patients were randomly assigned, with 66 allocated to the fullerene group and 66 to the trolamine group. The patients had a mean age of 58.0 years (standard deviation, 11.1), and 39 (29.5%) were female. The incidence of grade ≥2 ARD was significantly lower in the fullerene group than in the trolamine group. In the fullerene group, 34.8% of patients (95% CI, 24.5 to 46.9) developed grade ≥2 ARD, compared with 83.3% of patients in the trolamine group (95% CI, 72.6 to 90.4). CONCLUSION: In this prospective, randomized clinical trial, fullerene significantly reduced the incidence of ARD compared with trolamine.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Liu Z, Liu X, Li Z, et al. Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial. J Clin Oncol. 2026. PMID: 41861269. doi:10.1200/JCO-25-02264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。